Precision Oncology Africa
Precision oncology in Africa needs more than sequencing. It needs linked diagnosis, pathology, immunohistochemistry, tissue context, treatment records, recurrence, survival, and real-world African outcomes.
The missing data layer
African cancer patients remain underrepresented in precision oncology datasets, molecular oncology research, biomarker discovery pipelines, and treatment-response evidence systems.
Many datasets separate genomic results from pathology diagnosis, IHC, clinical context, treatment received, recurrence, survival, and real-world system constraints.
The Kebeza view
Precision oncology in Africa should be built as a linked evidence platform, not just a sequencing project.
What an African precision oncology platform should link
- Clinical history and district-level context.
- Pathology diagnosis and tumor classification.
- Immunohistochemistry and biomarker status.
- Tissue availability and quality for sequencing.
- Tumor-normal sequencing where feasible.
- Treatment received and pathway decisions.
- Response, recurrence, progression, and survival follow-up.
For patients
Future African precision oncology should connect diagnosis to treatment options and real-world outcomes.
For researchers
Linked clinico-pathology-genomic data can support discovery, trial design, and biomarker validation.
For partners
The platform creates a serious implementation layer for sequencing, oncology, pharma, and AI-health collaborators.
Funding-ready concept
With appropriate partners, the African Precision Oncology Atlas could begin with a focused pilot and expand into a broader African cancer evidence platform.
Not overclaiming
This is a proposed implementation and research infrastructure initiative. Its value lies in building the data layer Africa needs for future precision oncology.
Related Kebeza work
Partner on African precision oncology infrastructure
Kebeza is positioning African cancer diagnosis, pathology, genomics, and treatment response as one linked evidence system.